
    
      This study is a Phase I dose-escalation open-label study to determine the MTD of M2ES in
      Subjects With Advanced Solid Tumors the recommended Phase II dose.The recommended dose and
      regimen of M2ES will be selected to perform the pharmacokinetic study profiles.
    
  